CODX vs. ICAD, PYPD, APYX, KRMD, SRTS, BLUA, BWAY, ALUR, STIM, and PDEX
Should you be buying Co-Diagnostics stock or one of its competitors? The main competitors of Co-Diagnostics include iCAD (ICAD), PolyPid (PYPD), Apyx Medical (APYX), KORU Medical Systems (KRMD), Sensus Healthcare (SRTS), BlueRiver Acquisition (BLUA), BrainsWay (BWAY), Allurion Technologies (ALUR), Neuronetics (STIM), and Pro-Dex (PDEX).
iCAD (NASDAQ:ICAD) and Co-Diagnostics (NASDAQ:CODX) are both small-cap computer and technology companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, community ranking, valuation and profitability.
Co-Diagnostics received 45 more outperform votes than iCAD when rated by MarketBeat users. Likewise, 63.34% of users gave Co-Diagnostics an outperform vote while only 62.81% of users gave iCAD an outperform vote.
In the previous week, iCAD had 2 more articles in the media than Co-Diagnostics. MarketBeat recorded 6 mentions for iCAD and 4 mentions for Co-Diagnostics. iCAD's average media sentiment score of 1.25 beat Co-Diagnostics' score of 0.94 indicating that Co-Diagnostics is being referred to more favorably in the news media.
iCAD presently has a consensus target price of $5.00, suggesting a potential upside of 226.80%. Co-Diagnostics has a consensus target price of $2.00, suggesting a potential upside of 94.17%. Given Co-Diagnostics' higher probable upside, analysts plainly believe iCAD is more favorable than Co-Diagnostics.
iCAD has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500. Comparatively, Co-Diagnostics has a beta of -0.65, indicating that its stock price is 165% less volatile than the S&P 500.
24.6% of iCAD shares are owned by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are owned by institutional investors. 12.0% of iCAD shares are owned by company insiders. Comparatively, 2.4% of Co-Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
iCAD has a net margin of -15.20% compared to iCAD's net margin of -582.36%. Co-Diagnostics' return on equity of -14.00% beat iCAD's return on equity.
iCAD has higher revenue and earnings than Co-Diagnostics. iCAD is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.
Summary
iCAD beats Co-Diagnostics on 11 of the 16 factors compared between the two stocks.
Get Co-Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CODX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CODX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Co-Diagnostics Competitors List
Related Companies and Tools
